Phase 3 ABTECT Trial evaluating obefazimod for moderately to severely active ulcerative colitis (“UC”) reaches 1,003 of 1,224 participants, representing 82% of target enrollment. Enrollment completion ...
The connection between business and society is not a choice—it is a necessity. Having worked in various industries for over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback